Michel Alexander Steiner (Michel A Steiner)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 13

Top Topics

Rheumatoid Arthritis

Interstitial Lung Disease

Prefrontal Cortex

Top Venues

Journal of psychopharmacology (Oxford, England)

NPJ Parkinson's disease

Journal of medicinal chemistry

The International journal of eating disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Michel Alexander Steiner
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinson's disease 10 (1) (2024)
Michel Alexander Steiner, Luca Botticelli, Giorgio Bergamini, Emanuela Micioni Di Bonaventura, John Gatfield, Jodi T Williams, Alexander Treiber, Catherine Vaillant, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura
Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder. The International journal of eating disorders 57 (7) (2024)
Giorgio Bergamini, Sean Durkin, Michel Alexander Steiner
Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. Journal of psychopharmacology (Oxford, England) 38 (3) (2024)
Giorgio Bergamini, Sean Durkin, Michel Alexander Steiner
Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. Journal of psychopharmacology (Oxford, England) 38 (3) (2024)
Michel Alexander Steiner
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinson's disease 10 (1) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry 67 (4) (2024)
Giorgio Bergamini, Sean Durkin, Michel Alexander Steiner
Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. Journal of psychopharmacology (Oxford, England) 38 (3) (2024)
Michel Alexander Steiner
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinson's disease 10 (1) (2024)
Giorgio Bergamini, Sean Durkin, Michel Alexander Steiner
Selective orexin 1 receptor antagonism does not affect effort-based responding for sucrose reward in rats. Journal of psychopharmacology (Oxford, England) (2024)
Michel Alexander Steiner, Luca Botticelli, Giorgio Bergamini, Emanuela Micioni Di Bonaventura, John Gatfield, Jodi T Williams, Alexander Treiber, Catherine Vaillant, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura
Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder. The International journal of eating disorders (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry 67 (4) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry (2024)
Michel Alexander Steiner, Michael Toeroek-Schafroth, Maria-Elena Giusepponi, Lisa Dacome, Michela Tessari
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats. Journal of psychopharmacology (Oxford, England) (2023)